NPCE NeuroPace Inc
- Stocks
- Healthcare
- NASDAQ: NPCE
Price (delayed)
$11.79
Market cap
$383.88M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.93
Enterprise value
$443.67M
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating
Highlights
NeuroPace's EPS has increased by 27% YoY and by 6% QoQ
NeuroPace's gross profit has increased by 23% YoY and by 4.7% from the previous quarter
NPCE's equity has dropped by 61% year-on-year and by 18% since the previous quarter
NeuroPace's quick ratio has decreased by 11% YoY and by 6% QoQ
Key stats
What are the main financial stats of NPCE
Market
Valuations
Earnings
Shares outstanding
32.56M
Market cap
$383.88M
Enterprise value
$443.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
43.92
Price to sales (P/S)
4.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.55
Revenue
$79.91M
Gross profit
$59.09M
Operating income
-$21.67M
Net income
-$27.14M
EBIT
-$18.34M
EBITDA
-$16.57M
Free cash flow
-$18.26M
Per share
Balance sheet
Liquidity
EPS
-$0.93
EPS diluted
-$0.93
Free cash flow per share
-$0.63
Book value per share
$0.27
Revenue per share
$2.74
TBVPS
$3.25
Total assets
$94.65M
Total liabilities
$86.63M
Debt
$73.34M
Equity
$8.01M
Working capital
$66.18M
Debt to equity
9.15
Current ratio
5.37
Quick ratio
4.34
Net debt/EBITDA
-3.61
Margins
Efficiency
Dividend
EBITDA margin
-20.7%
Gross margin
73.9%
Net margin
-34%
Operating margin
-27.1%
Return on assets
-28.3%
Return on equity
-258.1%
Return on invested capital
-12.9%
Return on capital employed
-23.1%
Return on sales
-23%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NPCE stock price
How has the NeuroPace stock price performed over time
Intraday
0.86%
1 week
4.8%
1 month
-10.07%
1 year
-15.6%
YTD
5.36%
QTD
-4.07%
Financial performance
How have NeuroPace's revenue and profit performed over time
Revenue
$79.91M
Gross profit
$59.09M
Operating income
-$21.67M
Net income
-$27.14M
Gross margin
73.9%
Net margin
-34%
NeuroPace's operating margin has increased by 35% YoY and by 10% from the previous quarter
The net margin has increased by 33% YoY and by 7% from the previous quarter
NeuroPace's gross profit has increased by 23% YoY and by 4.7% from the previous quarter
NPCE's revenue is up by 22% year-on-year and by 4.5% since the previous quarter
Growth
What is NeuroPace's growth rate over time
Valuation
What is NeuroPace stock price valuation
P/E
N/A
P/B
43.92
P/S
4.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.55
NeuroPace's EPS has increased by 27% YoY and by 6% QoQ
NPCE's equity has dropped by 61% year-on-year and by 18% since the previous quarter
The price to book (P/B) is 59% higher than the last 4 quarters average of 27.6
NPCE's revenue is up by 22% year-on-year and by 4.5% since the previous quarter
NPCE's price to sales (P/S) is 13% more than its last 4 quarters average of 3.8
Efficiency
How efficient is NeuroPace business performance
NeuroPace's ROE has plunged by 68% YoY and by 26% from the previous quarter
NeuroPace's return on sales has increased by 39% YoY and by 9% QoQ
NPCE's ROIC is up by 20% year-on-year and by 3.7% since the previous quarter
The company's return on assets rose by 11% YoY
Dividends
What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NPCE.
Financial health
How did NeuroPace financials performed over time
NPCE's total assets is 9% higher than its total liabilities
NPCE's total assets is down by 12% YoY
NeuroPace's quick ratio has decreased by 11% YoY and by 6% QoQ
NeuroPace's debt to equity has surged by 161% YoY and by 22% QoQ
NPCE's equity has dropped by 61% year-on-year and by 18% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.